Bavarian Nordic A/S (OMX: BAVA, OTC-Nasdaq Intl Select Designation: BVNRY) is a biotechnology company with their common stock listed on Nasdaq Copenhagen. Bavarian Nordic joined the Nasdaq International Designation today, July 23, 2018, to increase the visibility of their Level 1 ADRs with US investors. The visibility & IR services that the Nasdaq International Designation provides will help assist Bavarian Nordic with its communication with US investors and highlight their ADRs that trade under the symbol BVNRY. Bavarian Nordic, with a US market cap of $966 million, joins other recent Nordic companies that have become members of Nasdaq International Designation for their ADRs, which include Carlsberg A/S with $18.6 billion in market cap USD and Lundbeck with $13.6 billion market cap USD.
Bavarian Nordic focuses on research, development, and manufactures cancer immunotherapies and vaccines for infectious diseases. Bavarian Nordic operates worldwide.
The Nasdaq International Designation program is designed for non-US-based companies that have Level 1 American Depository Receipts or Canadian companies that have shares that trade on the over-the-counter (OTC) market.
We look forward to helping our members grow their brand, increase liquidity and shape their personal message to the investment community. If you are interested in the Nasdaq International Designation Program, contact me at Bob.McCooey@nasdaq.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Nasdaq's International Designation is a comprehensive platform for Level 1 ADRs and Canadian companies.Learn More